Pharmacokinetics and efficacy of lorazepam in the treatment of pediatric status epilepticus
|
Principal Investigator
|
PI Home Department
|
Source of Support
|
Dates
|
Total Cost
|
|
Jim Chamberlain & Cheryl Vance
|
Emergency Medicine
|
National Institute of Health (NIH)
|
09/2004 - 12/31/2007
|
$66,000
|
Funded by the NIH to meet the needs of the FDA under the Best Pharmaceuticals for Children Act, the objectives of this study are to determine the pharmacokinetics of lorazepam in children, and its efficacy for the treatment of pediatric status epilepticus. Lorazepam is a commonly used drug for pediatric seizures but is not FDA approved for children. PECARN will ultimately conduct an RCT of lorazepam versus diazepam for the treatment of status epilepticus. UC Davis is one of 11 participating PECARN sites.
